ArticleDiabetes, obesity & metabolism2025
Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Sleep and obesity-known interactions and open questions.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Review
- Prevalence of Pre-Clinical Obesity Among US Adults Receiving Medical and Surgical Obesity Treatment.Obesity (Silver Spring, Md.) · 2026Article
- Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings.Health affairs scholar · 2026Article
- Review
- Trends in Incidence and Prevalence of Acute Pancreatitis in the United States: A Population-Based Analysis from 1995 to 2024.Digestive diseases and sciences · 2026Article
- Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?International journal of molecular sciences · 2025Review
- The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.Current atherosclerosis reports · 2025Review
- GLP-1 receptor agonists in the context of cancer: the road ahead.American journal of physiology. Cell physiology · 2025 · on this mapReview
- Health Disparities in Obesity Treatment Outcomes, Access, and Utilization.Current obesity reports · 2025Review
- Inflammatory and lipotoxicity mechanisms in obesity related CKD.Frontiers in nephrology · 2025Review
- Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need.Archives of medical science : AMS · 2025Article
- Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.Journal of obesity · 2025Review
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
aimsTo characterize trends in the initiation of newer anti-obesity medications (AOMs) and determine factors associated with their use among obese/overweight populations. MATERIALS AND
methodsThis study utilized electronic health record data from OneFlorida+ (2015-2024). Adults eligible for AOMs were included, defined as having a body mass index (BMI) ≥30 kg/m
resultsOf 319,949 adults, 1.8% initiated newer AOMs. Semaglutide accounted for 77.9% of initiations, tirzepatide 19.7% and liraglutide 17.8%. Initiation trends showed liraglutide uptake peaked at 5% in 2018 but declined afterward, while semaglutide and tirzepatide uptake increased exponentially since 2022. Odds of initiation were lower for Black (aOR [95% CI]: 0.87 [0.80-0.94]) and Hispanic (0.84 [0.78-0.91]) groups versus Whites, and for Medicaid (0.69 [0.63-0.76]) and uninsured (0.81 [0.74-0.87]) patients versus privately insured. Higher odds were associated with being female, middle-aged, having more outpatient visits and visiting endocrinologists.
conclusionsThe initiation of newer AOMs among overweight and obese populations remains low, but uptake has increased exponentially since 2022. Our findings reveal significant disparities in obesity care, highlighting the importance of addressing inequities in AOM access to improve obesity outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.